NCT01023724View on ClinicalTrials.gov

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

February 28, 2010

Conditions
Post Operative Anterior Chamber Inflammation (Flare)
Interventions
DRUG

Ketorolac Tromethamine 0.45%

Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.

DRUG

Bromfenac 0.09%

Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively

Trial Locations (1)

18702

Bucci Laser Vision Institute, Wilkes-Barre

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Bucci Laser Vision Institute

OTHER

NCT01023724 - A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) | Biotech Hunter | Biotech Hunter